Company intelligence / Profile preview

Nanjing NingQi Medicine Science and Technology

Nanjing, Jiangsu, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Nanjing NingQi Medicine Science and Technology is an active Chinese pharmaceutical company focused on oncology. It sponsors clinical trials for both traditional Chinese medicine formulations and modern biologics. Its lead programs include ChangTai Keli for colon cancer in Phase 2/3 studies, and Endostar combined with chemotherapy for advanced non-small cell lung squamous carcinoma in a Phase 4 trial. No recent published results are available; trial statuses are listed as "unknown."

Therapeutic areas: Oncology
Modalities: Traditional Chinese medicine formulationSmall moleculeRecombinant protein
Industry: Biotech

Drug pipeline

2 assets

ChangTai Keli

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nanjing NingQi Medicine Science and Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing NingQi Medicine Science and Technology.

Explore the full profile